Proto-Oncogene Proteins c-ret
"Proto-Oncogene Proteins c-ret" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.
| Descriptor ID |
D051096
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.087 D12.776.395.550.200.188.500 D12.776.543.131.500 D12.776.543.750.630.217 D12.776.624.664.700.194
|
| Concept/Terms |
Proto-Oncogene Proteins c-ret- Proto-Oncogene Proteins c-ret
- Proto Oncogene Proteins c ret
- c-ret, Proto-Oncogene Proteins
- Receptor Tyrosine Kinase RET
- ret Proto-Oncogene Proteins
- Proto-Oncogene Proteins, ret
- ret Proto Oncogene Proteins
- Proto-Oncogene Protein c-ret
- Proto Oncogene Protein c ret
- c-ret, Proto-Oncogene Protein
- c-ret Protein
- Proto-Oncogene Protein Ret
- Proto Oncogene Protein Ret
- Ret, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-ret".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-ret".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-ret" by people in this website by year, and whether "Proto-Oncogene Proteins c-ret" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 8 | 8 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 4 | 4 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 6 | 8 |
| 2008 | 3 | 4 | 7 |
| 2009 | 3 | 2 | 5 |
| 2010 | 3 | 3 | 6 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 3 | 5 |
| 2016 | 3 | 1 | 4 |
| 2017 | 10 | 3 | 13 |
| 2018 | 5 | 2 | 7 |
| 2019 | 1 | 1 | 2 |
| 2020 | 7 | 3 | 10 |
| 2021 | 6 | 3 | 9 |
| 2022 | 0 | 9 | 9 |
| 2023 | 1 | 8 | 9 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-ret" by people in Profiles.
-
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20; 42(27):3187-3195.
-
Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid. 2024 Sep; 34(9):1177-1180.
-
Genomic characterization of cervical lymph node metastases in papillary thyroid carcinoma following the Chornobyl accident. Nat Commun. 2024 Jun 13; 15(1):5053.
-
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. Ann Endocrinol (Paris). 2024 Apr; 85(2):118-126.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332.
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.
-
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.
-
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. 2023 09; 7:e2300252.